cyrilzakka/clinical-trials huggingface dataset:
A Comparison of Volatile Anesthesia and Total Intravenous Anesthesia (TIVA)

In this study, investigators wanted to investigate the effect of volatile anesthesia and total intravenous anesthesia (TIVA) on ecchymosis, edema, and intraoperative bleeding in rhinoplasty.

Routine monitorization (blood pressure, pulse, oxygen saturation with pulse oximetry and electrocardiogram) will be applied to all patients taken into the operation room.

In Group P (TIVA), induction of anesthesia will be achieved with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 μ / kg fentanyl. Propofol and remifentanil will be used in the continuation of anesthesia.

In Group S (Volatile), anesthesia will be induced with 2 mg / kg propofol, 0.6 mg / kg rocuronium and 1 μ / kg fentanyl. 50% nitrous oxide + 50% oxygen and 2% sevoflurane will be used in the continuation of anesthesia.

All patients will receive 2 ml/kg/hour Ringer's lactate solution during the operation.

Eligibility Criteria:
Inclusion Criteria:

* Between 18 and 65 years
* Planned to rhinoplasty
* An American Society of Anesthesiologists score of 1 or 2

Exclusion Criteria:

* Steroid use
* Patients with coagulation disorders, •Rejected to participation
Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios

The purpose of the study is to investigate third trimester fetal renal artery doppler indices in borderline idiopathic isolated oligohydramnios and relationship between neonatal outcomes.

During a routine pregnancy examination at 34-37 weeks gestation, the fetus was evaluated using ultrasound with the Toshiba Xario 200 3.5-megahertz probe. Fetal biometric measurements were obtained and placental structure and the amniotic fluid amount were evaluated in four quadrants. After detailed ultrasonography of the fetus, eligible pregnant women were included in the study.

Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index \>5.0 and ≤8.0cm. After first ultrasound examination all patients in borderline isolated oligohydramnios group were hydrated with one to two liters of water daily. All patients monitored with non stress test and amniotic fluid index twice weekly until delivery after treatment with hydration.

For evaluating renal artery blood flow, an axial image of the fetal abdomen was obtained at the level of the fetal kidneys. Using color flow Doppler, the renal arteries were evaluated at the level of their origin from the abdominal aorta. The Doppler gate was placed within the lumen in a straight segment of the vessel. A minimum of three consecutive waveforms was used to calculate the PI. The umbilical artery Doppler measurements were studied in a free loop of cord, far from the fetus and placenta. pulsatile index and resistance index values were recorded.

The study consisted of two groups. The first group was formed of the patients who had normal amniotic volume and meets the inclusion criteria. In second group the investigators included patients who diagnosed borderline idiopathic isolated oligohydramnios. After delivery the investigators compared fetal renal artery doppler indices and neonatal outcomes between groups.

Eligibility Criteria:
Inclusion Criteria:

* singleton pregnancies
* between 34-37 gestational weeks
* the age of them ranged from 18 to 35 years

Exclusion Criteria:

* uteroplacental insufficiency
* preeclampsia
* chronic hypertension
* collagen vascular disease
* nephropathy
* chromosomal abnormalities
* congenital abnormalities, especially those associated with impaired urine production
* growth restriction
* ruptured fetal membranes
* twin pregnancies
The Association Between Food Timing and Composition on Gastrointestinal Injury, Stress Hormone and Gastrointestinal Complains.

The study aimed to check the influence of timing and composition of diet on markers of gut injury, endotoxemia and stress.

The research protocol includes detailed food intake analysis, including timing and composition, markers related to the neuroendocrine pathway cortisol, and observations of individually experienced symptoms. Moreover, the study also explores intestinal injury and endotoxemia parameters, such as I-FABP, CLDN-3, and LBP. As a first goal, this study investigates the timing and composition of food intake concerning changes in gut integrity, cortisol levels, and gastrointestinal symptoms. Investigators explored whether an athlete's nutritional intake influences any GI disturbance induced by high-intensity exercise. As a second goal, Investigators tried to connect symptoms and markers from both pathways with gastrointestinal complaints. Investigators hypothesised that cortisol levels would be more profound than other studied parameters in gastrointestinal symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Membership in Polish Rowing Team,
* minimum five years of training,
* total training time minimum of 240 minutes,
* filling out a food diary,
* finishing 2000-meter ergometer test.

Exclusion Criteria:

* Probiotics within the last three months,
* prebiotics within the last three months
* antibiotic therapy within the last three months,
* dietary regime,
* gastrointestinal diseases,
* lactose intolerance
In-Hospital Comprehensive Geriatric Assessment in Aged Acute Medical Patients

The purpose of this study is to compare acute ill elderly medical patients in a geriatric department with general medical departments, and to examine the effects of comprehensive geriatric assessment in the geriatric setting compared with general medical care.

Design:

1) a cross-sectional study followed by 2) a subgroup study by retrospective follow-up

Eligibility Criteria:
Inclusion Criteria:

* patients admitted to the departments of medicine at Aarhus University Hospital either through the emergency medical ward or directly to the medical wards in the period from January 1, 2009 to December 31, 2010.

Exclusion Criteria:

* patients admitted to the neurology-, cardiology-, nephrology- or haematology departments, and patients discharged directly to their homes from the emergency medical ward.
Analyse Cardio-respiratory Patterns in Order to Early Detect the Clinical Complications in the Hemodialysis Patients

The incidence and prevalence of dialysis in Taiwan remains higher as compared to past several years. The number of dialysis reported about 6-7 million people each year and the 2014 full-year cost estimation was about 330 million NTDs. According to age-standardized population statistics in 1995, the number of dialysis per million population in 2006 year were 372.2 people, 381.9 people in 2012 year and the annual growth rate of 0.43 percent recorded.

EarlySense system is certified by TFDA, FDA and many other countries, which consists of mainly two parts. One for the sensing element, which placed under the mattress and the other one is AC-powered display panel bed. This system has the ability to monitor the patients physiological functions just be in contact via bed. When the patient laid on bed, the sensor which is placed under the bed would detects heart rate, breathing rate and activity level as well as other physiological signals. The system is also able to distinguish between patients in bed and out of bed during the operation to save the patient's records and information (including heart rate, respiratory rate and level of activity, and may render trends). The system is also have capability for real-time data transmission information which includes a warning to the nurses' station or other monitoring center of the screen by providing real-time information to nurse.

In this research project, we will use EarlySense equipment for continuous monitoring the dialysis patient's physiological data along with clinical data such as A. acute complications such as rapid changes in blood pressure, respiratory rate, movements of patients and Nausea or vomiting, etc phenomenon's) B. Lab examination data C. Status of patient whether patients hospitalized or not and patient death occurred or not. The study is expected to have a pilot study for more than three months' duration. Through this EarlySense continuous monitoring and gather the data, we will analyse to develop a prediction model and confirmed with indicators. Evidences from these analytics would help to propose ways to improve it and implement Positive predictive validity models.


Eligibility Criteria:
Inclusion Criteria:

* above 20 years old and under hemodialysis

Exclusion Criteria:

* patient with coronary artery disease or under treatment for coronary artery disease and patient with fever, any kind of infection, or taking antibiotics
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.


Eligibility Criteria:
Inclusion criteria:

* Primary diagnosis of Social Anxiety Disorder.
* Willing to restrict alcohol to a limited intake.

Exclusion criteria:

* History of schizophrenia, schizoaffective disorder or a bipolar disorder.
* Left-handed.
* Suffer from claustrophobia.
* Any reason why subject could not go into the fMRI, for example have metal implants.
Improving Patient Memory for Treatment for Mild Cognitive Impairment

The main empirical question to be addressed is: What types of memory support are most potent for patients who are experiencing a mild cognitive impairment (MCI) relative to non-MCI patients?

People experiencing mild cognitive impairment (MCI) may benefit from adding memory support to treatment-as-usual. Adding memory support may be an innovative way to improve patient memory for treatment, adherence to treatment and outcome.

The key question is: What types of memory support are most potent for MCI patients relative to non-MCI patients?

The aim of the proposed research is to assess patient memory for treatment and the impact of adding memory support for people who are and are not experiencing MCI. The investigators will also compare the effectiveness of constructive vs. non-constructive memory supports for people who are experiencing MCI compared to people who are not experiencing MCI.

Hypotheses:

1. Recall of the content of treatment will be lower in the MCI group relative to the non-MCI group.
2. Constructive memory support will be more effective for the non-MCI group relative to the MCI group.
3. Non-constructive memory support will be more effective for the MCI group relative to the non-MCI group.

The outcomes are: (1) patient memory for the content of treatment session and (2) the number and accuracy of thoughts and applications of the therapy points delivered. The investigators will also collect ratings of the acceptability of the treatment and the memory supports that are delivered.

This dataset will also be used to better understand the sleep and circadian challenges that people with and without MCI report via the SCID for sleep disorders and the PROMIS scales.

Eligibility Criteria:
Inclusion Criteria:

1. Participants 60 years and older will be recruited.
2. Fluent in English.
3. Experiencing some difficulties relating to sleep and circadian functioning and (d) a score of 19-25 on the Montreal Cognitive Assessment (for the MCI group) and score 26-30 on the Montreal Cognitive Assessment (for the non-MCI group) (e) Have a computer to use and an internet connection and (f) be able to attend sessions weekly and on the same day each week.

Exclusion criteria:

1. Presence of an active and progressive mental or physical illness or neurological degenerative disease;
2. Night shift work \>2 nights per week in the past 3 months;
3. Not able and willing to participate in and/or complete the assessments and participate in the treatment.
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy

To compare the prognosis and adverse reactions of unresectable hepatocellular carcinoma receiving stereotactic radiotherapy combined with hepatic arterial chemoembolization and conversion hepatectomy


Eligibility Criteria:
Inclusion Criteria:

* Unresectable HCC patients were diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
* Patients who received SBRT plus TACE have tumor regression, and surgical experts assess that R0 resection could be achieved
* CP-A or B classification;
* Eastern Cooperative Oncology Group (ECOG) score 0-1;
* Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
* ICG R15≤10%;
* Normal effective liver volume \>30%;
* patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.

Exclusion Criteria:

-the patients receive other treatments (such as targeted treatment, immune checkpoint inhibitors,etc) after CK-SBRT plus TACE.
Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?

Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial.

The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use.


Eligibility Criteria:
Inclusion Criteria:

* Patients with AR-PML
* Diagnosed between January 2008 and December 2015
* Followed in one of the four University Hospitals' Infectious Diseases Departments

Exclusion Criteria:
Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

Patients with Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with dynamic allodynia of the lower extremities, patients with Type I or II diabetes and pain distal symmetric sensorimotor polyneuropathy with no dynamic allodynia of the lower extremities, or patients with idiopathic distal predominantly sensory neuropathy participated in a Phase IV clinical trial to assess the efficacy of lidocaine patches in treating painful diabetic neuropathy or idiopathic distal sensory neuropathy.


Eligibility Criteria:
Inclusion Criteria:

* At Sites 1, 2, and 3 - Had painful diabetic polyneuropathy of 3 or more months duration
* At Site 1 only - Had clinical signs and symptoms of distal predominantly sensory polyneuropathy of 3 or more months duration. Diagnosis of predominantly sensory polyneuropathy were to be confirmed by either nerve conduction studies (large fiber sensory or sensorimotor axonal neuropathy) or by abnormal epidermal innervations on punch skin biopsy (distal leg/proximal thigh) (Herrmann et al., 1999; Holland et al., 1997)
* Had an average daily pain rating for the baseline week of pain ratings equal to 4 or greater on the 0 to 10 numerical pain rating scale
* Had at least 2 hours of moderate or severe pain intensity due to polyneuropathy daily in the immediately prior 3-month period
* Were using stable analgesic drug therapy for at least 1 week (regimen and dosages) prior to screening visit, with the exception of acetaminophen and lidocaine for patients undergoing a punch skin biopsy

Exclusion Criteria:

* Had prior treatment with topical lidocaine, except for use with the punch skin biopsy procedure
* Were currently under treatment with Class I antiarrhythmic agents (such as tocainide and mexiletine)
* Had any other pain more severe than the painful diabetic or idiopathic neuropathy
* Had open skin lesions in the area where the lidocaine patches were to be applied
Predictors for Admission to Emergency Department More Than 48 Hours

In Demark acutely admitted patients are supposed to stay in the Emergency Department (ED) bed ward if the anticipated duration of stay is less than 48 hours.

However, it is not a trivial matter to estimate duration of stay for emergency patients. a number of factors affect this, eg. social background, disease, hospital organisation.

The aim of this study is to analyse whom are the best among the health staff to predict the length of stay: ED nurses, admitting doctors og the specialist, and to analyse if a number of variables can be used to improve the prediction.


Eligibility Criteria:
Inclusion Criteria:

all patients admitted to the Emergency Department -

Exclusion Criteria:

Children less than 15 years patients transferred from other hospitals

-
Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer

Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. Little is known about the molecular mechanisms governing TCP in lung adenocarcinoma (LUAD), i.e. the most frequent lung cancer subtype. The investigators recently identified prognostic 7-miRNAs/10-mRNAs signatures which accurately identified aggressive LUAD among patients with early-stage disease (Stage I). Furthermore, the investigators showed that such tumors show TCP features i.e. mesenchymal and stem-cell traits, high-metastatic potential. Here, the investigators aim to explore by RNAseq and by immunophenotyping at a single-cell level (scRNAseq/AbSeq), the molecular features of aggressive LUAD to unveil the mechanisms triggering TCP. The investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive LUAD.


Eligibility Criteria:
Inclusion Criteria:

* patients diagnosed with lung adenocarcinoma
* treatment naive
* undergoing primary surgery

Exclusion Criteria:

* patients with a previous history of cancer
* previously treated by chemio/immuno/radio-therapy
Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions

The purpose of this study is to investigate the safety and efficacy of drug-coated balloon angioplasty for the treatment of chronic total occlusions patients with chronic total occlusion (CTO) lesion.

Recruited CTO patients will be divided into two groups: those undergoing PCI of drug-coated balloon (DCB group), and those undergoing PCI of drug eluting stent implantation (DES group). The primary outcome assessed will be the late lumen loss evaluation at a 12-month of follow-up appointment. Secondary outcomes include occurrence of major cardiac events (MACEs), myocardial viability, operate success, quality of life changes which will be compared to a baseline measurement.

Eligibility Criteria:
Inclusion Criteria

* Patients between 18 and 80 years of age
* Must comply all the evaluations and follow-up protocols
* Clinical diagnosis of CTO detected using coronary angiography (at least one other major vessel should have exhibited no less than 75% stenosis)
* Patients should present with left ventricular ejection fraction (LVEF) above 35% determined using transthoracic echocardiography
* CTO located in an epicardial coronary artery with a reference diameter of ≥ 2.5 mm

Exclusion Criteria

* Patients have suffered from acute myocardial infarction within the previous 3 months
* Lesion located in the left main artery (stenosis ≥50%)
* Clinical diagnosis of rheumatic valvular disease
* Clinical diagnosis of severe arrhythmia
* With history of revascularization within the CTO artery
* Lesions unsuitable for PCI
* Severely abnormal hematopoietic systems, such as platelet counts \<100 x 109/L or \> 700 x 109/ L and white blood cell counts \< 3 x 109/L
* Patients with active bleeding or bleeding tendencies (active ulcers, short-term ischemic stroke, history of hemorrhagic stroke, intracranial space occupying lesions, recent craniocerebral trauma, and other bleeding or bleeding tendency)
* Patients with severe coexisting condition including: severe renal function dysfunction \[Glomerular filtration rate (GFR) less than 60 ml/min • 1.73 m2), severe hepatic dysfunction \[glutamic-pyruvic transaminase (ALT) or glutamic-oxal acetic transaminase (ALT) elevated more than three times that of the upper limit of the normal reference\], severe heart failure (NYHA classification III-IV), acute infectious diseases and immune disorders, tumors, surgery within 3 months, a life expectancy less than 12 months, pregnancy or planning to become pregnant, history of allergy or adverse reactions to aspirin, clopidogrel, ticagrelor, stains, contrast material, anticoagulant, or stents
* Patients cannot tolerate dual antiplatelet treatment (DAPT)
* Patients are unable to communicate due to cognitive impairment, auditory or visual impairment
* Patients are participating in another trial for medication or an apparatus and in which the main endpoint has not been reached, or plan to participate in a clinical trial within 12 months of the intervention
BCT-HA Kit for Dehydrated and Wrinkled Skin

This study will assess the efficacy of Cellular MatrixTM BCT-HA Kit treatment compared to placebo condition on revitalization and skin rejuvenation on the midface. Particular attention will be made to the safety aspects, as well as the histological consequences of treatment.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPPA Authorization
* Healthy men and women, ages 30 - 65 years of age
* Subjects with Fitzpatrick photo skin type I-VI
* Subjects with moderate to severe nasolabial folds contour deficiencies or other facial wrinkles. Degree of nasolabial folds or other facial wrinkles will be determined on the basis of the Wrinkles Severity Rating Scale
* Subjects who agree not to have any other procedures of affecting skin quality (microdermabrasion, peels, acne treatments, toxin, fillers etc.) for the duration of the study
* Subjects who understand the study and are able to follow study instructions and are willing to attend the required study visits.
* Subjects who agree to be photographed for research purposes and their identity may not be concealed in these photographs.

Exclusion Criteria:

* Subjects who have had any kind of aesthetic therapy (peeling, laser, ultrasound, toxins, fillers) in the facial area during the last 6 months
* Presence of implant in the facial area to treat
* Contraindications to the use of antiseptics (Biseptine, Amukine)
* Subjects who have an active or known skin inflammation or infection within the treatment area.
* Subjects who have an active or known acute skin allergies
* Subjects who have a known allergy to hyaluronic acid
* Subjects who have any other dermatologic conditions including acne, rosacea, eczema, psoriasis, actinic keratosis, severe sun damage, infection, or scars within the treatment area.
* Subjects of child-bearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy, or bilateral oophorectomy.
* Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy.
* Subjects who have been diagnosed with diabetes
* Subjects who are Immunosuppressed
* Subjects who are HIV+ / VHB+ / VHC+
* Subjects who have had/will have a COVID vaccine within 2 weeks of study participation
* Subjects who have had/will have a dental procedure within 4 weeks of study participation
* Subjects with a history of severe bee allergy